phospho-FANCD2(Ser1404)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 13141R
英文名称phospho-FANCD2(Ser1404)
中文名称磷酸化FANCD2抗体
别 名FANCD2 (phospho S1404); FANCD2 (phospho Ser1404); p-FANCD2 (phospho S1404); FA 4; FA D2; FA4; FAC D2; FACD 2; FACD; FACD2; FAD; FAD2; FANC D2; FANCD 2; FANCD; Protein FACD2; Type 4 Fanconi pancytopenia; FACD2_HUMAN; Fanconi anemia group D2 protein; Protein FACD2.
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 细胞生物 染色质和核信号 转录调节因子
抗体来源Rabbit
克隆类型Polyclonal
phospho-FANCD2(Ser1404)抗体交叉反应 Human, Pig, Cow, Horse, Rabbit, Sheep,
产品应用ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 Flow-Cyt=1μg/Test ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量162kDa
细胞定位细胞核
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human FANCD2 around the phosphorylation site of Ser1404:QN(p-S)QE
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-FANCD2(Ser1404)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
Fanconi Anemia (FANC) is a human autosomal-recessive cancer susceptibility disorder characterized by congenital defects, progressive bone marrow failure, and cellular hypersensitivity to mitomycin C (MMC). The FANC subunit D2 protein is vital for cellular resistance to DNA cross-linking and the arrest of DNA synthesis after ionizing radiation. DNA damage activates the monoubiquitination of FANC D2, targeting nuclear foci containing the BRCA 1 protein.
Function:
Required for maintenance of chromosomal stability. Promotes accurate and efficient pairing of homologs during meiosis. Involved in the repair of DNA double-strand breaks, both by homologous recombination and single-strand annealing. May participate in S phase and G2 phase checkpoint activation upon DNA damage. Plays a role in preventing breakage and loss of missegregating chromatin at the end of cell division, particularly after replication stress. Required for the targeting, or stabilization, of BLM to non-centromeric abnormal structures induced by replicative stress. Promotes BRCA2/FANCD1 loading onto damaged chromatin. May also be involved in B-cell immunoglobulin isotype switching.
Subunit:
Interacts directly with FANCE and FANCI. Interacts with USP1 and MEN1. The ubiquitinated form specifically interacts with BRCA1 and BLM. Both the nonubiquitinated and the monoubiquitinated forms interact with BRCA2; this interaction is mediated by phosphorylated FANCG and the complex also includes XCCR3. The ubiquitinated form specifically interacts with MTMR15/FAN1 (via UBZ-type zinc finger), leading to recruit MTMR15/FAN1 to sites of DNA damage. Interacts with DCLRE1B/Apollo.
Subcellular Location:
Nucleus. Note=Concentrates in nuclear foci during S phase and upon genotoxic stress. At the onset of mitosis, excluded from chromosomes and diffuses into the cytoplasm, returning to the nucleus at the end of cell division. Observed in a few spots localized in pairs on the sister chromatids of mitotic chromosome arms and not centromeres, one on each chromatids. These foci coincide with common fragile sites and could be sites of replication fork stalling. The foci are frequently interlinked through BLM-associated ultra-fine DNA bridges. Following aphidicolin treatment, targets chromatid gaps and breaks.
Tissue Specificity:
Highly expressed in germinal center cells of the spleen, tonsil, and reactive lymph nodes, and in the proliferating basal layer of squamous epithelium of tonsil, esophagus, oropharynx, larynx and cervix. Expressed in cytotrophoblastic cells of the placenta and exocrine cells of the pancreas (at protein level). Highly expressed in testis, where expression is restricted to maturing spermatocytes.
Post-translational modifications:
Monoubiquitinated on Lys-561 during S phase and upon genotoxic stress by FANCL in complex with E2 ligases UBE2T or UBE2W (isoform 1 and isoform 2). Deubiquitinated by USP1 as cells enter G2/M, or once DNA repair is completed. Monoubiquitination requires the joint intervention of the FANC core complex, including FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, and FANCM, and proteins involved in cell cycle checkpoints and DNA repair, including RPA1, ATR, CHEK1 and BRCA1, and is mediated by FANCL/PHF9. Ubiquitination is required for binding to chromatin, interaction with BRCA1, BRCA2 and MTMR15/FAN1, DNA repair, and normal cell cycle progression, but not for phosphorylation on Ser-222 or interaction with MEN1.
Phosphorylated in response to various genotoxic stresses by ATM and/or ATR. Upon ionizing radiation, phosphorylated by ATM on Ser-222 and Ser-1404. Phosphorylation on Ser-222 is required for S-phase checkpoint activation, but not for ubiquitination, foci formation, or DNA repair. In contrast, phosphorylation by ATR on other sites may be required for ubiquitination and foci formation.
Defects in FANCD2 are a cause of Fanconi anemia complementation group D type 2 (FANCD2) [MIM:227646]. A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.
Gene ID:
2177
phospho-FANCD2(Ser1404)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-FANCD2(Ser1404)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 phospho-GSK-3 Beta(Ser21+Ser29) 磷酸化糖原合酶激酶3β抗体
合格 phospho-GSK-3 Beta(Ser21) 磷酸化糖原合酶激酶3β抗体
合格 phospho-G3BP1(Ser232) 磷酸化Ras GTP酶活化蛋白结合蛋白1抗体
合格 Phospho-NMDAR2B (Tyr1336) 磷酸化谷氨酸受体2B抗体
合格 phospho-HDAC1 (Ser423+Ser421) 磷酸化组蛋白去乙酰化酶1抗体
合格 Seladin 1 24脱氢胆固醇还原酶抗体
合格 phospho-HOMER3 (Thr36) 磷酸化HOMER3蛋白抗体
合格 phospho-IKK gamma(Ser43) 磷酸化KB抑制蛋白激酶γ抗体
合格 phospho-IL-1R1(Tyr496) 磷酸化白介素1受体1抗体
合格 phospho-IL-7Ra (Tyr449) 磷酸化白细胞介素-7受体a抗体
合格 phospho-IRS1 (Ser312) 磷酸化胰岛素受体底物-1抗体
合格 phospho-IKK beta(Ser471) 磷酸化KB抑制蛋白激酶β抗体
合格 Phospho-c-Kit(Ser741) 磷酸化原癌基因c-kit抗体
合格 Phospho-c-Kit(Ser721) 磷酸化原癌基因c-kit抗体
合格 Phospho-LRP6(Thr1479) 磷酸化低密度脂蛋白受体相关蛋白6抗体
合格 phospho-Tau (Ser235) 磷酸化微管相关蛋白抗体
合格 phospho-Tau (Thr212) 磷酸化微管相关蛋白抗体
合格 phospho-Tau (Thr205) 磷酸化微管相关蛋白抗体
合格 phospho-Tau (Ser356) 磷酸化微管相关蛋白抗体
合格 PP1C gamma 蛋白磷酸酶γ1抗体
合格 合格 PPAP2A 磷酸脂磷酸水解酶1抗体
合格 phospho-MEK2 (Thr394) 磷酸化丝裂原活化蛋白激酶激酶2抗体
合格 phospho-MEK5(Ser142) 磷酸化丝裂原活化蛋白激酶激酶5抗体
合格 phospho-MEK5(Ser129) 磷酸化丝裂原活化蛋白激酶激酶5抗体
合格 phospho-MEK5(Ser137) 磷酸化丝裂原活化蛋白激酶激酶5抗体
合格 合格 合格 Phospho-TAK1(Ser192) 磷酸化转化生长因子β活化激酶1